A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis

What is the goal of the study?

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators. This is an open-label, multiple-ascending dose study of ARCT-032 in adults with CF who are not on CFTR modulator therapy. After successful screening, eligible participants enrolled in cohort 4 will receive nebulized ARCT-032 for 12 weeks and will then be followed for an additional 12 weeks for safety.

Who can participate in the study?

1) Adults diagnosed with CF 2) Not eligible for CFTR modulator therapy or not taking CFTR modulators  3) FEV1 45% to 90%

Study Team:

• PI (Study Doctor): Meghan McGarry
• Study Team Member: CF Study Team, [email protected]